Success Metrics

Clinical Success Rate

83.3%

Based on 10 completed trials

Completion Rate

83%(10/12)

Active Trials

7(24%)

Results Posted

30%(3 trials)

Terminated

2(7%)

Phase Distribution

Ph phase_2

52%

Ph not_applicable

14%

Ph phase_4

Ph phase_1

31%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution29 total trials

Phase 1Safety & dosage

9(31.0%)

Phase 2Efficacy & side effects

15(51.7%)

Phase 4Post-market surveillance

1(3.4%)

N/ANon-phased studies

4(13.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

10 of 14 finished

Non-Completion Rate

28.6%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Completed(10)

Terminated(4)

Other(7)

Detailed Status

Completed10

unknown7

Recruiting5

Terminated2

Active, not recruiting2

Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Phase 19 (31.0%)

Phase 215 (51.7%)

Phase 41 (3.4%)

N/A4 (13.8%)

Trials by Status

terminated27%

unknown724%

active_not_recruiting27%

completed1034%

withdrawn27%

recruiting517%

not_yet_recruiting13%

Recent Activity

7 active trials

Showing 5 of 29

recruitingphase_2

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

NCT05514899

recruitingnot_applicable

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more

NCT05514899Phase 2

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

Recruiting

NCT06878417Not Applicable

Cannabinoids for Osteoarthritis Pain Effectiveness Trial

Recruiting

NCT06840899Phase 2

CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

Recruiting

NCT05067387Phase 1

Evaluation of Oral THC and CBD in Men and Women

Not Yet Recruiting

NCT05066308Phase 2

Cannabidiol for Reduction of Brain Neuroinflammation

Recruiting

NCT06014424Phase 2

Cannabidiol Medication Intervention Trial

Recruiting

NCT06261489Phase 2

Cannabis (THC vs. CBD) in Multiple Sclerosis

Active Not Recruiting

NCT04611347Phase 2

Is Topical CBD Effective in Treating Thumb Joint Arthritis

Completed

NCT04286594Phase 2

A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety

Terminated

NCT04283019Phase 1

The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions

Completed

NCT04439955Phase 2

Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients

Completed

NCT04778644Phase 1

Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task

Active Not Recruiting

NCT03537950Not Applicable

Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder

Completed

NCT05170451Phase 2

Topical CBD for Musculoskeletal Pain

Withdrawn

NCT04741477Phase 1

The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products

Completed

NCT05317013Phase 1

CBD in Postmenopausal Women With Osteopenia

Terminated

NCT02071862Phase 1

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Completed

NCT04768478Phase 4

CBD for Pain Reduction and Opioid Use After Ankle and Tibia Fracture ORIF

Withdrawn

NCT04686539Phase 1

Synthetic CBD as a Therapy for COVID-19

Unknown

NCT03840512Phase 2

An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

Unknown

Drug Details

Intervention Type: DRUG
Total Trials: 29